iohexol has been researched along with Chronic Kidney Diseases in 71 studies
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this clinical trial is to compare iodixanol with iohexol for the incidence of contrast-induced nephropathy in patients with chronic heart failure with reduced ejection fraction who are currently undergoing coronary angiography or angioplasty." | 9.24 | Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty. ( Ge, Z; Li, Y; Shi, P; Song, M; Song, T; Sun, M, 2017) |
| "Among patients with CKD and albuminuria treated with dapagliflozin, an acute reduction in eGFR (from baseline to 2 weeks) is not associated with higher rates of CKD progression." | 5.41 | ( Bonno, M; Bridges, C; Chertow, GM; Correa-Rotter, R; Enoksen, IT; Eriksen, BO; Fuskevåg, OM; Georgiou, A; Greene, T; Gupta, S; Heerspink, HJL; Hirayama, M; Irwin, JM; Jenssen, TG; Johnson, JL; Jongs, N; Karaca-Mandic, P; Kashihara, N; Langkilde, AM; Mathisen, UD; McMurray, JJV; Melsom, T; Norvik, JV; Ogawa, M; Rossing, P; Rudisill, ME; Sen, S; Shiono, A; Simon, K; Sjöström, CD; Solbu, MD; Stefánsson, BV; Stefansson, V; Tanaka, S; Toto, RD; Toyoda, H; Wadsworth, DD; Wheeler, DC, 2021) |
| "The aim of this clinical trial is to compare iodixanol with iohexol for the incidence of contrast-induced nephropathy in patients with chronic heart failure with reduced ejection fraction who are currently undergoing coronary angiography or angioplasty." | 5.24 | Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty. ( Ge, Z; Li, Y; Shi, P; Song, M; Song, T; Sun, M, 2017) |
| "Preserum and postserum creatinine levels were retrospectively evaluated from 8 patients with stage 3-4 CKD who underwent tcd-CTA with 20 mL of Iohexol for fEVAR planning for the treatment of pararenal abdominal aortic aneurysms." | 3.83 | Ultralow Iodine Dose Transarterial Catheter-Directed CT Angiography for Fenestrated Endovascular Aortic Repair Planning. ( Burke, LM; Farber, MA; Isaacson, AJ; Vallabhaneni, R, 2016) |
| " GFR was estimated with the Chronic Kidney Disease and Epidemiology equation (CKD-EPI) and measured with a gold standard method (inulin or iohexol) not indexed (mGFR) or indexed to body surface area determined by the Dubois and Dubois formula with either real (mGFRr) or ideal (mGFRi) body weight." | 3.80 | Accuracy of GFR estimation in obese patients. ( Dubourg, L; Guebre-Egziabher, F; Hadj-Aissa, A; Juillard, L; Lemoine, S; Nguyen-Tu, MS; Sens, F, 2014) |
| " Linear regression modeling was used to evaluate the association of serum leptin level with glomerular filtration rate calculated using the plasma iohexol disappearance curve, demographics, body mass index (BMI), and cardiovascular risk factors, including inflammatory cytokines, insulin resistance, and serum lipid levels." | 3.80 | Correlates of leptin in children with chronic kidney disease. ( Furth, S; Mitsnefes, M; Nehus, E; Warady, B, 2014) |
| "Sodium bicarbonate has been suggested as a possible strategy for prevention of contrast medium-induced nephropathy, a common cause of renal failure associated with prolonged hospitalization, increased health care costs, and substantial morbidity and mortality." | 2.73 | Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. ( Aharonian, VJ; Brar, SS; Burchette, RJ; Desai, N; Jorgensen, MB; Kotlewski, A; Ree, M; Shah, AI; Shen, AY, 2008) |
| " The dataset was split into two groups, one to develop the population pharmacokinetic (POPPK) model (n = 103) and the other (n = 48) to estimate the predictive performances of the various GFR estimation methods." | 1.56 | Assessment of the glomerular filtration rate (GFR) in kidney transplant recipients using Bayesian estimation of the iohexol clearance. ( Barbet, C; Barin-Le Guellec, C; Benz-de Bretagne, I; Besombes, J; Blasco, H; Büchler, M; Gatault, P; Halimi, JM; Riff, C, 2020) |
| "Iohexol clearance was an estimation of the mean glomerular filtration rate over 24 hours." | 1.51 | Glomerular Hyper- and Hypofiltration During Acute Circulatory Failure: Iohexol-Based Gold-Standard Descriptive Study. ( Barin-Le Guellec, C; Benz-de Bretagne, I; Benzékri-Lefèvre, D; Bodet-Contentin, L; Bretagnol, A; Ehrmann, S; Halimi, JM; Helms, J; Le Tilly, O; Mercier, E; Meziani, F; Salmon Gandonnière, C, 2019) |
| " To evaluate the safety of the procedure, we aimed to review all immediate adverse reactions that could be related to iohexol administration in our group's 25 years worth of experience." | 1.48 | Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience. ( Aparicio, MC; Cannata, A; Carrara, F; Diadei, O; Ferrari, S; Gaspari, F; Perico, N; Perna, A; Remuzzi, G; Ruggenenti, P; Stucchi, N; Thakar, S; Trillini, M, 2018) |
| "To evaluate concordance between glomerular filtration rate (GFR) estimates (Cockcroft and Gault, modification of diet in renal diseases, chronic kidney disease epidemiology study group equations) for drug dosing in HIV-infected patients." | 1.46 | CKD-EPI equation: A suitable Glomerular Filtration Rate estimate for drug dosing in HIV-infected patients. ( Botelho-Nevers, E; Cazorla, C; Delanaye, P; Fafin, C; Frésard, A; Gagneux-Brunon, A; Guglielminotti, C; Lucht, F; Mariat, C; Moranne, O, 2017) |
| " The renal function was evaluated by (1) the dosage of plasmatic creatinine, (2) the GFR estimated with the Cockroft-Gault, Modification of Diet in Renal Disease (MDRD), and chronic kidney disease epidemiology collaboration (CKD-EPI) formulas, (3) the creatinine clearance (CC), and (4) the direct measurement of the GFR with a reference method (iohexol clearance)." | 1.46 | Preoperative Evaluation of the Renal Function before the Treatment of Abdominal Aortic Aneurysms. ( Alvarez, JC; Coggia, M; Coscas, R; Goeau-Brissonniere, O; Javerliat, I; Massy, Z; Sartorius, A; Vilaine, E; Wagner, S, 2017) |
| "Although hypertension is a risk factor for end-stage renal disease, this complication develops in only a minority of hypertensive patients." | 1.43 | Elevated blood pressure is not associated with accelerated glomerular filtration rate decline in the general non-diabetic middle-aged population. ( Eriksen, BO; Jenssen, TG; Mathisen, UD; Melsom, T; Schei, J; Solbu, MD; Stefansson, VTN; Wilsgaard, T, 2016) |
| "The relative incidence of long-term adverse effects between low-osmolar contrast media (LOCM) and iso-osmolar contrast media (IOCM) after coronary angiography is still unclear." | 1.43 | Long-Term Adverse Effects of Low-Osmolar Compared With Iso-Osmolar Contrast Media After Coronary Angiography. ( Chang, D; Ju, S; Lu, CQ; Tang, A; Wang, YC; Zhang, SJ, 2016) |
| "Iohexol clearance was measured and the precisions and bias of the various estimation equations were calculated." | 1.39 | Applicability of a different estimation equation of glomerular filtration rate in Turkey. ( Altiparmak, MR; Andican, ZG; Bolayirli, M; Serdengecti, K; Seyahi, N; Suleymanlar, G; Trabulus, S; Yalin, SF, 2013) |
| "Iohexol concentration was measured from dried blood spots on filter paper." | 1.39 | Estimating kidney function in HIV-infected adults in Kenya: comparison to a direct measure of glomerular filtration rate by iohexol clearance. ( Abraham, AG; Abuya, J; Hotta, M; Klotman, PE; Koima, WJ; M'mene, LB; Maier, P; Mboku, C; Owino Ong'or, W; Schwartz, GJ; Wools-Kaloustian, K; Wyatt, CM, 2013) |
| "The odds ratio of acute kidney failure on day 5 was 0." | 1.38 | Effect of renin-angiotensin-aldosterone system blockade therapy on incidence of contrast-induced nephropathy in patients with chronic kidney disease. ( Ghahramani, N; Lapsiwala, A; Parhizgar, A; Saadulla, L; Spatz, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (9.86) | 29.6817 |
| 2010's | 51 (71.83) | 24.3611 |
| 2020's | 13 (18.31) | 2.80 |
| Authors | Studies |
|---|---|
| Eide, TT | 1 |
| Hufthammer, KO | 1 |
| Brun, A | 3 |
| Brackman, D | 3 |
| Svarstad, E | 2 |
| Tøndel, C | 3 |
| Gupta, S | 1 |
| Georgiou, A | 1 |
| Sen, S | 1 |
| Simon, K | 1 |
| Karaca-Mandic, P | 1 |
| Shiono, A | 1 |
| Bonno, M | 1 |
| Toyoda, H | 1 |
| Ogawa, M | 1 |
| Tanaka, S | 1 |
| Hirayama, M | 1 |
| Johnson, JL | 1 |
| Wadsworth, DD | 1 |
| Rudisill, ME | 1 |
| Irwin, JM | 1 |
| Bridges, C | 1 |
| Melsom, T | 6 |
| Norvik, JV | 3 |
| Enoksen, IT | 2 |
| Stefansson, V | 1 |
| Mathisen, UD | 4 |
| Fuskevåg, OM | 1 |
| Jenssen, TG | 4 |
| Solbu, MD | 6 |
| Eriksen, BO | 6 |
| Jongs, N | 1 |
| Chertow, GM | 1 |
| Greene, T | 2 |
| McMurray, JJV | 1 |
| Langkilde, AM | 1 |
| Correa-Rotter, R | 1 |
| Kashihara, N | 1 |
| Rossing, P | 2 |
| Sjöström, CD | 1 |
| Stefánsson, BV | 1 |
| Toto, RD | 1 |
| Wheeler, DC | 1 |
| Heerspink, HJL | 1 |
| Fu, EL | 1 |
| Levey, AS | 4 |
| Coresh, J | 1 |
| Elinder, CG | 1 |
| Rotmans, JI | 1 |
| Dekker, FW | 1 |
| Paik, JM | 1 |
| Barany, P | 1 |
| Grams, ME | 2 |
| Inker, LA | 4 |
| Carrero, JJ | 2 |
| Enoksen, ITT | 1 |
| Rinde, NB | 1 |
| Svistounov, D | 2 |
| Pocar, P | 1 |
| Scarpa, P | 1 |
| Berrini, A | 1 |
| Cagnardi, P | 1 |
| Rizzi, R | 1 |
| Borromeo, V | 1 |
| Diprose, WK | 1 |
| Sutherland, LJ | 1 |
| Wang, MTM | 1 |
| Barber, PA | 1 |
| McKenna, M | 1 |
| Pelligand, L | 1 |
| Elliott, J | 1 |
| Cotter, D | 1 |
| Jepson, R | 1 |
| Riff, C | 1 |
| Besombes, J | 1 |
| Gatault, P | 1 |
| Barbet, C | 1 |
| Büchler, M | 1 |
| Blasco, H | 1 |
| Halimi, JM | 2 |
| Barin-Le Guellec, C | 2 |
| Benz-de Bretagne, I | 2 |
| Kalyesubula, R | 1 |
| Fabian, J | 2 |
| Nakanga, W | 1 |
| Newton, R | 1 |
| Ssebunnya, B | 1 |
| Prynn, J | 1 |
| George, J | 2 |
| Wade, AN | 1 |
| Seeley, J | 1 |
| Nitsch, D | 1 |
| Hansen, C | 1 |
| Nyirenda, M | 1 |
| Smeeth, L | 1 |
| Naicker, S | 1 |
| Crampin, AC | 1 |
| Tomlinson, LA | 1 |
| Seegmiller, JC | 1 |
| Ebert, N | 4 |
| Pierce, CB | 1 |
| Muñoz, A | 4 |
| Ng, DK | 1 |
| Warady, BA | 4 |
| Furth, SL | 4 |
| Schwartz, GJ | 7 |
| Couture, SJ | 1 |
| Tighiouart, H | 3 |
| Abraham, AG | 5 |
| Beck, GJ | 1 |
| Feldman, HI | 1 |
| Gudnason, V | 2 |
| Karger, AB | 1 |
| Eckfeldt, JH | 1 |
| Kasiske, BL | 1 |
| Mauer, M | 1 |
| Navis, G | 1 |
| Poggio, ED | 1 |
| Shlipak, MG | 1 |
| Currin, S | 1 |
| Gondwe, M | 1 |
| Mayindi, N | 1 |
| Chipungu, S | 1 |
| Khoza, B | 1 |
| Khambule, L | 1 |
| Snyman, T | 1 |
| Tollman, S | 1 |
| Shibata, S | 1 |
| Moniwa, N | 1 |
| Kuno, A | 1 |
| Kimura, A | 1 |
| Ohwada, W | 1 |
| Sugawara, H | 1 |
| Gocho, Y | 1 |
| Tanaka, M | 1 |
| Yano, T | 1 |
| Furuhashi, M | 1 |
| Tanno, M | 1 |
| Miki, T | 1 |
| Miura, T | 1 |
| Stefansson, VTN | 2 |
| Methven, S | 1 |
| Gasparini, A | 1 |
| Caskey, FJ | 1 |
| Evans, M | 1 |
| Song, T | 1 |
| Song, M | 1 |
| Ge, Z | 1 |
| Li, Y | 1 |
| Shi, P | 1 |
| Sun, M | 1 |
| Turner, ME | 1 |
| Laverty, KJ | 1 |
| Jeronimo, PS | 1 |
| Kaufmann, M | 1 |
| Jones, G | 1 |
| White, CA | 1 |
| Holden, RM | 1 |
| Adams, MA | 1 |
| Gagneux-Brunon, A | 1 |
| Botelho-Nevers, E | 1 |
| Delanaye, P | 4 |
| Lucht, F | 1 |
| Frésard, A | 1 |
| Cazorla, C | 1 |
| Guglielminotti, C | 1 |
| Fafin, C | 1 |
| Mariat, C | 1 |
| Moranne, O | 1 |
| Leion, F | 1 |
| Hegbrant, J | 1 |
| den Bakker, E | 1 |
| Jonsson, M | 1 |
| Abrahamson, M | 1 |
| Nyman, U | 4 |
| Björk, J | 4 |
| Lindström, V | 2 |
| Larsson, A | 2 |
| Bökenkamp, A | 1 |
| Grubb, A | 4 |
| Bukabau, JB | 1 |
| Sumaili, EK | 1 |
| Cavalier, E | 2 |
| Pottel, H | 1 |
| Kifakiou, B | 1 |
| Nkodila, A | 1 |
| Makulo, JRR | 1 |
| Mokoli, VM | 1 |
| Zinga, CV | 1 |
| Longo, AL | 1 |
| Engole, YM | 1 |
| Nlandu, YM | 1 |
| Lepira, FB | 1 |
| Nseka, NM | 1 |
| Krzesinski, JM | 1 |
| Gaspari, F | 2 |
| Thakar, S | 1 |
| Carrara, F | 2 |
| Perna, A | 1 |
| Trillini, M | 1 |
| Aparicio, MC | 1 |
| Diadei, O | 1 |
| Ferrari, S | 1 |
| Cannata, A | 1 |
| Stucchi, N | 1 |
| Ruggenenti, P | 1 |
| Remuzzi, G | 1 |
| Perico, N | 1 |
| Staples, A | 1 |
| Wong, C | 1 |
| Lima, SL | 1 |
| Porrini, E | 1 |
| Salmon Gandonnière, C | 1 |
| Helms, J | 1 |
| Le Tilly, O | 1 |
| Bretagnol, A | 1 |
| Bodet-Contentin, L | 1 |
| Mercier, E | 1 |
| Benzékri-Lefèvre, D | 1 |
| Meziani, F | 1 |
| Ehrmann, S | 1 |
| Fadrowski, JJ | 1 |
| Navas-Acien, A | 1 |
| Guallar, E | 1 |
| Weaver, VM | 1 |
| Altiparmak, MR | 1 |
| Seyahi, N | 1 |
| Trabulus, S | 1 |
| Yalin, SF | 1 |
| Bolayirli, M | 1 |
| Andican, ZG | 1 |
| Suleymanlar, G | 1 |
| Serdengecti, K | 1 |
| Wyatt, CM | 1 |
| Owino Ong'or, W | 1 |
| Abuya, J | 1 |
| Mboku, C | 1 |
| M'mene, LB | 1 |
| Koima, WJ | 1 |
| Hotta, M | 2 |
| Maier, P | 1 |
| Klotman, PE | 1 |
| Wools-Kaloustian, K | 1 |
| Hansson, LO | 1 |
| Flodin, M | 1 |
| Nordin, G | 1 |
| Friedman, AN | 1 |
| Moe, S | 1 |
| Fadel, WF | 1 |
| Inman, M | 1 |
| Mattar, SG | 1 |
| Shihabi, Z | 1 |
| Quinney, SK | 1 |
| Martus, P | 3 |
| van der Giet, M | 3 |
| Jakob, O | 3 |
| Schaeffner, ES | 2 |
| Lemoine, S | 1 |
| Guebre-Egziabher, F | 1 |
| Sens, F | 1 |
| Nguyen-Tu, MS | 1 |
| Juillard, L | 1 |
| Dubourg, L | 1 |
| Hadj-Aissa, A | 1 |
| Margolick, JB | 1 |
| Jacobson, LP | 1 |
| Darilay, AT | 1 |
| Kingsley, LA | 1 |
| Witt, MD | 1 |
| Palella, FJ | 1 |
| Maple-Brown, LJ | 1 |
| Ekinci, EI | 1 |
| Hughes, JT | 1 |
| Chatfield, M | 1 |
| Lawton, PD | 1 |
| Jones, GR | 1 |
| Ellis, AG | 1 |
| Sinha, A | 1 |
| Cass, A | 1 |
| Hoy, WE | 1 |
| O'Dea, K | 1 |
| Jerums, G | 1 |
| MacIsaac, RJ | 1 |
| Nehus, E | 1 |
| Furth, S | 2 |
| Warady, B | 1 |
| Mitsnefes, M | 1 |
| Chua, HR | 1 |
| Horrigan, M | 1 |
| Mcintosh, E | 1 |
| Bellomo, R | 1 |
| Wang, BB | 1 |
| Wu, Y | 1 |
| Qin, Y | 1 |
| Gong, MC | 1 |
| Shi, XM | 1 |
| Jing, HL | 1 |
| Li, F | 1 |
| Chen, CY | 1 |
| Song, HM | 1 |
| Li, XM | 1 |
| Liu, YH | 1 |
| Liu, Y | 1 |
| Tan, N | 1 |
| Chen, JY | 1 |
| Zhou, YL | 1 |
| Luo, JF | 1 |
| Yu, DQ | 1 |
| Li, LW | 1 |
| Li, HL | 1 |
| Ye, P | 1 |
| Ran, P | 1 |
| Okparavero, A | 2 |
| Aspelund, T | 1 |
| Andresdottir, MB | 1 |
| Eiriksdottir, G | 1 |
| Harris, T | 1 |
| Launer, L | 1 |
| Nikulasdottir, H | 1 |
| Sverrisdottir, JE | 1 |
| Gudmundsdottir, H | 1 |
| Noubary, F | 1 |
| Mitchell, G | 1 |
| Palsson, R | 1 |
| Indridason, OS | 1 |
| Loesment, A | 1 |
| Gaedeke, J | 2 |
| Kuhlmann, M | 1 |
| Bartel, J | 1 |
| Schuchardt, M | 2 |
| Tölle, M | 2 |
| Huang, T | 1 |
| Schaeffner, E | 1 |
| Samson, E | 1 |
| Allouche, S | 1 |
| Shema-Didi, L | 1 |
| Kristal, B | 1 |
| Eizenberg, S | 1 |
| Marzuq, N | 1 |
| Sussan, M | 1 |
| Feldman-Idov, Y | 1 |
| Ofir, P | 1 |
| Atar, S | 1 |
| Løchen, ML | 1 |
| Arntzen, KA | 1 |
| Bertelsen, G | 1 |
| Winther Eilertsen, BA | 1 |
| von Hanno, T | 1 |
| Herder, M | 1 |
| Njølstad, I | 2 |
| Mathiesen, EB | 1 |
| Salvador, CL | 2 |
| Mørkrid, L | 1 |
| Bjerre, A | 2 |
| Bolann, B | 2 |
| Bergan, S | 1 |
| Jouret, F | 1 |
| Le Goff, C | 1 |
| Hellberg, M | 1 |
| Höglund, P | 1 |
| Svensson, P | 1 |
| Abdulahi, H | 1 |
| Clyne, N | 1 |
| Schei, J | 1 |
| Wilsgaard, T | 1 |
| Isaacson, AJ | 1 |
| Burke, LM | 1 |
| Vallabhaneni, R | 1 |
| Farber, MA | 1 |
| Vart, P | 1 |
| Wang, YC | 1 |
| Tang, A | 1 |
| Chang, D | 1 |
| Lu, CQ | 1 |
| Zhang, SJ | 1 |
| Ju, S | 1 |
| Coscas, R | 1 |
| Wagner, S | 1 |
| Vilaine, E | 1 |
| Sartorius, A | 1 |
| Javerliat, I | 1 |
| Alvarez, JC | 1 |
| Goeau-Brissonniere, O | 1 |
| Coggia, M | 1 |
| Massy, Z | 1 |
| Boucquemont, J | 1 |
| Loubère, L | 1 |
| Metzger, M | 1 |
| Combe, C | 1 |
| Stengel, B | 1 |
| Leffondre, K | 1 |
| Brar, SS | 1 |
| Shen, AY | 1 |
| Jorgensen, MB | 1 |
| Kotlewski, A | 1 |
| Aharonian, VJ | 1 |
| Desai, N | 1 |
| Ree, M | 1 |
| Shah, AI | 1 |
| Burchette, RJ | 1 |
| Schneider, MF | 2 |
| Mak, RH | 1 |
| Kaskel, F | 1 |
| Korohoda, P | 1 |
| Zachwieja, K | 1 |
| Pietrzyk, JA | 1 |
| Sułowicz, W | 1 |
| Sterner, G | 1 |
| Ingebretsen, OC | 1 |
| Toft, I | 1 |
| Ristiniemi, N | 1 |
| Savage, C | 1 |
| Bruun, L | 1 |
| Pettersson, K | 1 |
| Lilja, H | 1 |
| Christensson, A | 1 |
| Kim, IY | 1 |
| Lee, SB | 1 |
| Lee, DW | 1 |
| Song, SH | 1 |
| Seong, EY | 1 |
| Kwak, IS | 1 |
| Maier, PS | 1 |
| Moxey-Mims, M | 1 |
| Dharnidharka, VR | 1 |
| Wyatt, C | 1 |
| Creamer, R | 1 |
| Hellinger, J | 1 |
| Leppo, M | 1 |
| Graham, H | 1 |
| Savage, K | 1 |
| Schmid, CH | 1 |
| Wallach, F | 1 |
| Krishnasami, Z | 1 |
| Kilbride, HS | 1 |
| Stevens, PE | 1 |
| Eaglestone, G | 1 |
| Knight, S | 1 |
| Carter, JL | 1 |
| Delaney, MP | 1 |
| Farmer, CK | 1 |
| Irving, J | 1 |
| O'Riordan, SE | 1 |
| Dalton, RN | 1 |
| Lamb, EJ | 1 |
| Frei, U | 1 |
| Kuhlmann, MK | 1 |
| Ziebig, R | 1 |
| Spatz, C | 1 |
| Saadulla, L | 1 |
| Lapsiwala, A | 1 |
| Parhizgar, A | 1 |
| Ghahramani, N | 1 |
| Laugharne, MJ | 1 |
| Paravasthu, M | 1 |
| Preston, A | 1 |
| Hill, KO | 1 |
| Sharma, SK | 1 |
| Kini, A | 1 |
| Briguori, C | 1 |
| Colombo, A | 1 |
| Airoldi, F | 1 |
| Morici, N | 1 |
| Sangiorgi, GM | 1 |
| Violante, A | 1 |
| Focaccio, A | 1 |
| Montorfano, M | 1 |
| Carlino, M | 1 |
| Condorelli, G | 1 |
| Ricciardelli, B | 1 |
| Onbasili, AO | 1 |
| Yeniceriglu, Y | 1 |
| Agaoglu, P | 1 |
| Karul, A | 1 |
| Tekten, T | 1 |
| Akar, H | 1 |
| Discigil, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glomerular Filtration Rate in Children - a Methodological Study With Iohexol Clearance[NCT01092260] | 96 participants (Actual) | Observational | 2010-04-30 | Completed | |||
| A Multicenter, Open-label, Controlled Study to Investigate the Effect of Either LF111 or Drospirenone Chewable Tablets on Bone Mineral Density in Adolescent and Adult Women in Comparison With Non-users of Hormonal Contraceptive Methods[NCT05303636] | Phase 4 | 1,710 participants (Anticipated) | Interventional | 2022-03-28 | Recruiting | ||
| Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)[NCT00327860] | 1,100 participants (Actual) | Observational | 2003-10-31 | Active, not recruiting | |||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| A Randomized Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate[NCT00312117] | Phase 3 | 300 participants | Interventional | 2006-01-31 | Completed | ||
| Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill : A Multiple Center Randomized Clinical Trial (BICAR-ICU)[NCT02476253] | Phase 3 | 400 participants (Anticipated) | Interventional | 2015-05-05 | Recruiting | ||
| A Patient-centered Approach to Urinary Incontinence and Quality of Life in Children and Adolescents With Spina Bifida[NCT03410667] | 400 participants (Anticipated) | Interventional | 2019-12-01 | Recruiting | |||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| Prediction of Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With Acute Lymphoblastic Leukemia and Lymphoma[NCT02133599] | 23 participants (Actual) | Interventional | 2014-07-24 | Completed | |||
| GOOD-DAY: Efficacy of Gamification of an educatiOnal Training tO meDiterranean Diet on Weight and Metabolic Control in pAediatric obesitY: a Pilot Open-label Randomized Controlled Trial[NCT03154255] | 60 participants (Actual) | Interventional | 2017-10-03 | Completed | |||
| A Long-Term, Open-Label, Safety, Tolerability and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis[NCT01733316] | Phase 3 | 41 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| An Open-Label, Safety and Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naïve Patients With Cystinosis[NCT01744782] | Phase 3 | 17 participants (Actual) | Interventional | 2012-12-20 | Completed | ||
| Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System[NCT02235857] | 35 participants (Anticipated) | Interventional | 2015-05-03 | Recruiting | |||
| Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot[NCT02233322] | 8 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients[NCT01491919] | Phase 1 | 26 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Evaluation of the Performance of GFR Estimating Equations in HIV Positive Patients[NCT00905151] | 206 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| Diagnosis of Monoclonal Gammopathy of Renal Significance in Patients With Paraproteinemias[NCT03629561] | 15 participants (Anticipated) | Observational [Patient Registry] | 2019-02-23 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary analysis of WBC cystine was performed using the natural log transformed WBC cystine level; the log transformation is a normalizing transformation. For each participant, the difference between the morning and corresponding non-morning log WBC cystine value (non-morning minus morning) at each monthly visit during the Cystagon® phase (Months 1, 2, and 3) was computed and these differences were averaged. The average difference between morning and non-morning log WBC cystine value was similarly computed for each participant during the RP103 phase (Months 5, 6, and 7). The primary analysis compared within-subject pairs (Cystagon® phase paired with RP103 phase) of non-morning minus morning average differences of log WBC cystine level. (NCT01733316)
Timeframe: While taking Cystagon® (Months 1, 2, 3): within 15 minutes pre-morning (AM) and pre-non AM dose. During 3 months of RP103 (Months 5, 6, 7): 30 minutes post-AM and post-evening (PM) dose.
| Intervention | log [nmol ½ cystine/mg protein] (Mean) |
|---|---|
| Cystagon® Phase | -0.229 |
| RP103 Phase | 0.080 |
"Participants who reported halitosis (bad breath) as a side effect while receiving Cystagon® were asked to participate in a substudy to investigate the concentration of DMS in expired air after the administration of study medication. To assess halitosis during study medication treatment, the steady state PK samples of cysteamine and DMS were collected over a 6 hour period when Cystagon® was administered and over a 12 hour period when RP103 was administered." (NCT01733316)
Timeframe: While taking Cystagon® (Month 1, 2 or 3): Within 15 minutes prior to morning dose, 30 minutes post-dose, 1, 2, 4 and 6 hours post-dose. While taking RP103 (Month 5, 6, or 7): 30 minutes after morning dose and 1, 2, 3, 4, 6, 8, 10, 12 hours post-dose
| Intervention | hr*mg/L (Mean) | |
|---|---|---|
| Cystagon® dosing period | RP103 dosing period | |
| Halitosis Substudy Participants | 7.8 | 9.4 |
"Participants who reported halitosis (bad breath) as a side effect while receiving Cystagon® were asked to participate in a substudy to investigate the concentration of DMS in expired air after the administration of study medication. To assess halitosis during study medication treatment, the steady state PK samples of cysteamine and DMS were collected over a 6 hour period when Cystagon® was administered and over a 12 hour period when RP103 was administered." (NCT01733316)
Timeframe: While taking Cystagon® (Month 1, 2 or 3): Within 15 minutes prior to morning dose 30 min post-dose, 2, 3, 4 and 6 hours post-dose. While taking RP103 (Month 4, 5, or 7): Within 15 min. prior to morning dose. 1, 2, 3, 4, 5, 6, 8, 10, 12 hours post dose
| Intervention | nmol/L (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cystagon®, within 15 minutes prior to dose | Cystagon®, 30 minutes post dose | Cystagon®, 1 hour post morning dose | Cystagon®, 2 hours post morning dose | Cystagon®, 3 hours post morning dose | Cystagon®, 4 hours post morning dose | Cystagon®, 6 hours post morning dose | RP103, within 15 minutes prior to dose | RP103, 1 hour post morning dose | RP103, 2 hours post morning dose | RP103, 3 hours post morning dose | RP103, 4 hours post morning dose | RP103, 5 hours post morning dose | RP103, 6 hours post morning dose | RP103, 8 hours post morning dose | RP103, 10 hours post morning dose | RP103, 12 hours post morning dose | |
| Halitosis Substudy Participants | 4.7 | 4.7 | 6.9 | 11.9 | 11.2 | 8.8 | 4.4 | 4.6 | 5.4 | 5.1 | 7.7 | 8.6 | 11.2 | 8.5 | 5.7 | 5.2 | 4.3 |
"Participants who reported halitosis (bad breath) as a side effect while receiving Cystagon® were asked to participate in a substudy to investigate the concentration of dimethylsulfide (DMS) in expired air after the administration of study medication. To assess halitosis during study medication treatment, the steady state pharmacokinetic (PK) samples of cysteamine and DMS were collected over a 6 hour period when Cystagon® was administered and over a 12 hour period when RP103 was administered." (NCT01733316)
Timeframe: While taking Cystagon® (Month 1, 2 or 3): Within 15 minutes prior to morning dose, 30 minutes post-dose, 1, 2, 4 and 6 hours post-dose. While taking RP103 (Month 5, 6, or 7): 30 minutes after morning dose and 1, 2, 3, 4, 6, 8, 10, 12 hours post-dose
| Intervention | mg/L (Mean) | |
|---|---|---|
| Cystagon® dosing period | RP103 dosing period | |
| Halitosis Substudy Participants | 3.5 | 2.9 |
"Participants who reported halitosis (bad breath) as a side effect while receiving Cystagon® were asked to participate in a substudy to investigate the concentration of DMS in expired air after the administration of study medication. To assess halitosis during study medication treatment, the steady state PK samples of cysteamine and DMS were collected over a 6 hour period when Cystagon® was administered and over a 12 hour period when RP103 was administered." (NCT01733316)
Timeframe: While taking Cystagon® (Month 1, 2 or 3): Within 15 minutes prior to morning dose, 30 minutes post-dose, 1, 2, 4 and 6 hours post-dose. While taking RP103 (Month 5, 6, or 7): 30 minutes after morning dose and 1, 2, 3, 4, 6, 8, 10, 12 hours post-dose
| Intervention | hour (Mean) | |
|---|---|---|
| Cystagon® dosing period | RP103 dosing period | |
| Halitosis Substudy Participants | 1.2 | 3.2 |
AE: any untoward medical occurrence that does not necessarily have a causal relationship with study drug. SAE: any untoward medical occurrence that at any dose: results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect; or is medically significant, and though not included in the above list, is an important medical event, according to the Investigator. Treatment-emergent adverse events (TEAEs) occurred after first dose of study drug. Clinically significant abnormalities in laboratory values (hematology, blood chemistry, urinalysis), electrocardiograms (ECGs), vital signs, and physical examinations were to be reported as adverse events and so are included in this summary of TEAEs (NCT01733316)
Timeframe: From first dose of study drug to 7 days after last dose. Median duration of exposure was 91 days (range 82-108) for Cystagon® phase, 119 days (range 98-137) for the RP103 phase, and 861 days (range 30 - 1350) during the long-term RP-103 phase.
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| At least 1 TEAE | At least 1 TEAE-related to study drug | At least 1 grade ≥ 3 TEAE | At least 1 serious TEAE | At least 1 TEAE leading to discontinuation | |
| Cystagon® Phase | 31 | 4 | 5 | 5 | 0 |
| Long-Term Phase | 32 | 18 | 13 | 13 | 1 |
| RP103 Phase | 38 | 20 | 4 | 6 | 0 |
Blood samples were collected and plasma cysteamine concentration was determined using liquid chromatography. The maximum observed plasma concentration (Cmax) of cysteamine was determined directly from the data. (NCT01744782)
Timeframe: 30 minutes after the morning RP103 dose at Month 6 (prior to Protocol Amendment 1) or 0 (pre-dose), 30 minutes, 2, 3, 4, 6, 8, 10, and 12 hours after the morning RP103 dose at Month 6 for those enrolled under Protocol Amendment 1 or later
| Intervention | mg/L (Mean) |
|---|---|
| RP103 | 1.26 |
Safety was assessed by the incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (SAEs). An AE/adverse experience was any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. For additional information regarding adverse events, please see the safety section of the record. (NCT01744782)
Timeframe: Day 1 through study exit
| Intervention | Participants (Count of Participants) |
|---|---|
| RP103 | 17 |
Blood samples were collected and plasma cysteamine concentration was determined using liquid chromatography. The time of the maximum observed plasma concentration (Tmax) of cysteamine was determined directly from the data. (NCT01744782)
Timeframe: 30 minutes after the morning RP103 dose at Month 6 (prior to Protocol Amendment 1) or 0 (pre-dose), 30 minutes, 2, 3, 4, 6, 8, 10, and 12 hours after the morning RP103 dose at Month 6 for those enrolled under Protocol Amendment 1 or later
| Intervention | minutes (Mean) |
|---|---|
| RP103 | 199 |
Blood samples were collected and plasma cysteamine concentration was determined using liquid chromatography. AUC values were estimated using non-compartmental analysis methods. AUClast was defined as the area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (720 minutes). AUCinf was defined as the area under the plasma concentration-versus-time curve from time 0 to infinity. (NCT01744782)
Timeframe: 30 minutes after the morning RP103 dose at Month 6 (prior to Protocol Amendment 1) or 0 (pre-dose), 30 minutes, 2, 3, 4, 6, 8, 10, and 12 hours after the morning RP103 dose at Month 6 for those enrolled under Protocol Amendment 1 or later
| Intervention | min*mg/L (Mean) | |
|---|---|---|
| AUClast | AUCinf | |
| RP103 | 206 | 231 |
Blood samples were taken 30 minutes after the morning RP103 dose at each study visit to determine White Blood Cell (WBC) cystine concentration. WBC cystine concentrations were determined using liquid chromatography. (NCT01744782)
Timeframe: Day 1, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12, Month 6, Month 9, Month 12, Month 15, Month 18, Study Exit
| Intervention | nmol 1/2 Cystine/mg protein (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | Week 2 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Study Exit | |
| RP103 | 3.1709 | 2.2899 | 1.8474 | 2.3403 | 0.9589 | 1.1219 | 1.1828 | 2.7250 | 2.0196 | 0.8012 | 1.2443 | 0.7356 | 0.8197 |
Potassium values will be obtained at Baseline and Day 14 prior to the final dose of study drug. Mean calculated from the two measurements. (NCT01491919)
Timeframe: At baseline visit and Day 14 prior to final study dose.
| Intervention | mEq/L (Mean) |
|---|---|
| Low Dose: Lisinopril | 0.1 |
| Medium Dose: Lisinopril | -0.3 |
| High Dose: Lisinopril | 0.3 |
Change in urine protein/creatinine obtained as follows: Mean change (worst post-dose from baseline) presented for urine protein/creatinine ratio. Geometric mean of the ratio (worst post-dose / baseline with Geometric Coefficient of Variation percent (CV%) and greatest decrease presented for eGFR by dose group. Two patients in the high dose group had an evaluable urine protein/creatinine change. (NCT01491919)
Timeframe: Baseline to worst post-dose before Day 14 (+/- 3 days)
| Intervention | mg/mg (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | -0.45 |
| Medium Dose: Lisinopril | -0.08 |
| High Dose: Lisinopril | -0.74 |
"The eGFR at entry will need to be ≥ 30 ml/min/1.73m^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitor (ACEI) mediated reduction in kidney function.~Largest eGFR percent decrease from baseline reported in results section." (NCT01491919)
Timeframe: Baseline to Day 14 (+/- 3 days)
| Intervention | percentage (Number) |
|---|---|
| Low Dose: Lisinopril | 15 |
| Medium Dose: Lisinopril | 12 |
| High Dose: Lisinopril | 21 |
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of AUC. Geometric mean was calculated from all measurements. (NCT01491919)
Timeframe: Day 14 (+/- 3 days) of lisinopril therapy at hours 0 (pre-dose) and 1,2,4,5,8,12 and 24 hrs after dose
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | 298 |
| Medium Dose: Lisinopril | 640 |
| High Dose: Lisinopril | 702 |
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of Cmax. Geometric mean was calculated from all measurements. (NCT01491919)
Timeframe: Day14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose
| Intervention | ng/ml (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | 20.9 |
| Medium Dose: Lisinopril | 47.7 |
| High Dose: Lisinopril | 58.0 |
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CL/F. Geometric mean was calculated from all measurements. (NCT01491919)
Timeframe: Day 14 (+/- 3 d) of dose at 0 hour and at 1, 2, 4, 5, 8, 12, and 24 hrs after dose
| Intervention | L/h/70 kg (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | 17.9 |
| Medium Dose: Lisinopril | 18.6 |
| High Dose: Lisinopril | 32.8 |
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of plasma lisinopril concentration. Medium was calculated from all measurements. (NCT01491919)
Timeframe: Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose
| Intervention | hours (Median) |
|---|---|
| Low Dose: Lisinopril | 5.0 |
| Medium Dose: Lisinopril | 5.0 |
| High Dose: Lisinopril | 4.5 |
At the Day 14 (±3 days) visit, blood (1 mL) will be collected at 0 hour (pre-dose) and at 1, 2, 4, 5, 8, 12 and 24 hours post-lisinopril dose for determination of CLrenal. Geometric mean was calculated from all measurements. (NCT01491919)
Timeframe: Day 14 (+/- 3 d) of dose at 0 hour and 1, 2, 4, 5, 8, 12, and 24 hrs after dose.
| Intervention | L/h/70 kg (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | 3.4 |
| Medium Dose: Lisinopril | 3.4 |
| High Dose: Lisinopril | 6.8 |
The eGFR at entry will need to be ≥ 30 ml/min/1.73m^2 to minimize concerns about an acute angiotensin-converting enzyme inhibitors (ACE-I)-mediated reduction in kidney function. eGFR ratio was computed from the worst post-dose value divided by the Baseline value. (NCT01491919)
Timeframe: Baseline to Day 14 (+/- 3 days)
| Intervention | ratio (Geometric Mean) |
|---|---|
| Low Dose: Lisinopril | 1 |
| Medium Dose: Lisinopril | 1.02 |
| High Dose: Lisinopril | 0.89 |
Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements (note: the participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40. The mean from the blood pressure measurements was calculated. (NCT01491919)
Timeframe: Screening to Day 14 to 40
| Intervention | mmHg (Mean) | |
|---|---|---|
| eGFR 30-59 ml/min per 1.73m2 (n=2, 2, 0) | eGFR >=60 ml/min per 1.73m2 (n=5, 2, 0) | |
| Low Dose: Lisinopril | -6.0 | 3.4 |
| Medium Dose: Lisinopril | -6.5 | -3.0 |
"Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern.~Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit).~The mean of these measurements was calculated." (NCT01491919)
Timeframe: Baseline to Day 14 (+/-3 days)
| Intervention | mmHg (Mean) | |
|---|---|---|
| eGFR 30-59 ml/min per 1.73m^2 (n=3, 1, 0) | eGFR >=60 ml/min per 1.73m^2 (n=3, 5, 3) | |
| High Dose: Lisinopril | NA | -4.0 |
| Low Dose: Lisinopril | -4.0 | -9.0 |
| Medium Dose: Lisinopril | 7.0 | -6.0 |
Lisinopril SOC participants were not given the ambulatory blood pressure machine to obtain readings at home, as was the Lisinopril-naive participants. Instead BP measurements were obtained during screening visit and compared to the Day 14 to 40 visit measurements. Note: these participants were not required to attend a Day 14 (+/-3 day visit) but did need to attend sometime between Day 14 to Day 40 (inclusive). The mean of these blood pressure measurements was calculated. (NCT01491919)
Timeframe: Screening to Day 14 to 40
| Intervention | mmHg (Mean) | |
|---|---|---|
| eGFR 30-59 ml/min per 1.73m2 (n=2, 2, 0) | eGFR >=60 ml/min per 1.73m2 (n=5, 2, 0) | |
| Low Dose: Lisinopril | -6.0 | 6.4 |
| Medium Dose: Lisinopril | -1.0 | -1.0 |
"Ambulatory blood pressure readings were measured during the baseline/pre-study dose period using a SpaceLabs (Redmond, WA) device at home to avoid the confounding effects of venipuncture and abnormal sleep pattern.~Another blood pressure reading was performed at 1 day before the final dose of lisinopril (day before the last scheduled visit).~The mean from these measurements was calculated." (NCT01491919)
Timeframe: Baseline to Day 14 (+/- 3 days)
| Intervention | mmHg (Mean) | |
|---|---|---|
| eGFR 30-59 ml/min per 1.73m2 (n=3, 1, 0) | eGFR >+60 ml/min per 1.732 (n=3, 5, 3) | |
| High Dose: Lisinopril | NA | -11.3 |
| Low Dose: Lisinopril | -5.0 | -6.7 |
| Medium Dose: Lisinopril | -6.0 | -8.8 |
Number of Adverse Events (AEs) related and not related to study drug; number of Serious Adverse Events (SAEs) related and not related to study drug (NCT01491919)
Timeframe: First dose of study drug to 30 days after final study visit for AEs and until resolution for SAEs
| Intervention | events (Number) | ||||
|---|---|---|---|---|---|
| AEs | AE related to study drug | AEs not related to study drug | SAE | SAE not related to study drug | |
| Lisinopril Standard of Care (SOC) | 12 | 0 | 12 | 0 | 0 |
| Lisinopril-naive | 12 | 5 | 7 | 1 | 1 |
Overall bias, median difference (95% confidence interval), mL/min per 1.73 m^2, assessed as the median difference between the measured and estimated GFR across all estimated GFR levels, with positive values indicating an underestimation of measured GFR. (NCT00905151)
Timeframe: Blood samples for plasma iohexol clearance were taken at approximately 10, 30, 120, and 240 minutes post-iohexol dose.
| Intervention | mL/min per 1.73 m^2 (Median) | |||
|---|---|---|---|---|
| MDRD study | CKD-EPI creatinine | CKD-EPI cystatin C | CKD-EPI creatinin-cystatin | |
| HIV Positive | 10.9 | 5.4 | 4.3 | 6.4 |
2 reviews available for iohexol and Chronic Kidney Diseases
| Article | Year |
|---|---|
Measuring and Assessing Kidney Function.
Topics: Albuminuria; beta 2-Microglobulin; Chelating Agents; Contrast Media; Creatinine; Cystatin C; Edetic | 2016 |
Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials.
Topics: Contrast Media; Humans; Iohexol; Iopamidol; Kidney Diseases; Randomized Controlled Trials as Topic; | 2005 |
8 trials available for iohexol and Chronic Kidney Diseases
| Article | Year |
|---|---|
Accuracy of single intravenous access iohexol GFR in children is hampered by marker contamination.
Topics: Administration, Intravenous; Adolescent; Blood Specimen Collection; Child; Glomerular Filtration Rat | 2021 |
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; COVID-19; Cross-Sectional Studies; Diabetes Mellitus | 2021 |
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; COVID-19; Cross-Sectional Studies; Diabetes Mellitus | 2021 |
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; COVID-19; Cross-Sectional Studies; Diabetes Mellitus | 2021 |
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; COVID-19; Cross-Sectional Studies; Diabetes Mellitus | 2021 |
Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty.
Topics: Adult; Angioplasty, Balloon, Coronary; China; Contrast Media; Coronary Angiography; Double-Blind Met | 2017 |
Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Biomarkers; Contrast Media; Coronary A | 2016 |
Decline in measured glomerular filtration rate is associated with a decrease in endurance, strength, balance and fine motor skills.
Topics: Adult; Aged; Aged, 80 and over; Contrast Media; Cross-Sectional Studies; Disease Progression; Exerci | 2017 |
Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.
Topics: Aged; Contrast Media; Coronary Angiography; Diabetes Mellitus; Female; Glomerular Filtration Rate; H | 2008 |
Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.
Topics: Aged; Contrast Media; Coronary Angiography; Diabetes Mellitus; Female; Glomerular Filtration Rate; H | 2008 |
Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.
Topics: Aged; Contrast Media; Coronary Angiography; Diabetes Mellitus; Female; Glomerular Filtration Rate; H | 2008 |
Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.
Topics: Aged; Contrast Media; Coronary Angiography; Diabetes Mellitus; Female; Glomerular Filtration Rate; H | 2008 |
Improved estimation of glomerular filtration rate (GFR) by comparison of eGFRcystatin C and eGFRcreatinine.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Contrast Media; Creatinine; Cystatin C; Diagnostic Techn | 2012 |
Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Contrast Media; Coron | 2007 |
61 other studies available for iohexol and Chronic Kidney Diseases
| Article | Year |
|---|---|
Accuracy of GFR Estimating Equations in Patients with Discordances between Creatinine and Cystatin C-Based Estimations.
Topics: Adult; Cardiovascular Diseases; Creatinine; Cystatin C; Diabetes Mellitus; Glomerular Filtration Rat | 2023 |
Validation of eGFR for Detecting Associations Between Serum Protein Biomarkers and Subsequent GFR Decline.
Topics: Biomarkers; Blood Proteins; Creatinine; Cystatin C; Glomerular Filtration Rate; Humans; Iohexol; Ren | 2023 |
Diagnostic potential of simplified methods for measuring glomerular filtration rate to detect chronic kidney disease in dogs.
Topics: Animals; Dog Diseases; Dogs; Female; Glomerular Filtration Rate; Iohexol; Male; Prospective Studies; | 2019 |
Contrast-Associated Acute Kidney Injury in Endovascular Thrombectomy Patients With and Without Baseline Renal Impairment.
Topics: Acute Kidney Injury; Aged; Case-Control Studies; Contrast Media; Creatinine; Endovascular Procedures | 2019 |
Relationship between serum iohexol clearance, serum SDMA concentration, and serum creatinine concentration in non-azotemic dogs.
Topics: Animals; Arginine; Contrast Media; Creatinine; Dog Diseases; Dogs; Glomerular Filtration Rate; Iohex | 2020 |
Assessment of the glomerular filtration rate (GFR) in kidney transplant recipients using Bayesian estimation of the iohexol clearance.
Topics: Adult; Aged; Algorithms; Bayes Theorem; Female; Glomerular Filtration Rate; Humans; Iohexol; Kidney | 2020 |
How to estimate glomerular filtration rate in sub-Saharan Africa: design and methods of the African Research into Kidney Diseases (ARK) study.
Topics: Adult; Africa South of the Sahara; Female; Glomerular Filtration Rate; Humans; Iohexol; Malawi; Male | 2020 |
Measuring glomerular filtration rate with iohexol plasma disappearance: blood collection duration is essential for accurate glomerular filtration rate determinations.
Topics: Glomerular Filtration Rate; Humans; Iohexol; Renal Insufficiency, Chronic | 2020 |
Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease.
Topics: Adolescent; Biomarkers; Child; Child, Preschool; Creatinine; Female; Glomerular Filtration Rate; Hum | 2021 |
Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease.
Topics: Adolescent; Biomarkers; Child; Child, Preschool; Creatinine; Female; Glomerular Filtration Rate; Hum | 2021 |
Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease.
Topics: Adolescent; Biomarkers; Child; Child, Preschool; Creatinine; Female; Glomerular Filtration Rate; Hum | 2021 |
Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease.
Topics: Adolescent; Biomarkers; Child; Child, Preschool; Creatinine; Female; Glomerular Filtration Rate; Hum | 2021 |
A New Panel-Estimated GFR, Including β
Topics: Adolescent; Adult; Aged; Aged, 80 and over; beta 2-Microglobulin; Black or African American; Black P | 2021 |
Evaluating chronic kidney disease in rural South Africa: comparing estimated glomerular filtration rate using point-of-care creatinine to iohexol measured GFR.
Topics: Creatinine; ErbB Receptors; Glomerular Filtration Rate; Humans; Iohexol; Point-of-Care Systems; Rena | 2021 |
Involvement of necroptosis in contrast-induced nephropathy in a rat CKD model.
Topics: Acute Kidney Injury; Animals; Contrast Media; Disease Models, Animal; Iohexol; Kidney Tubules, Proxi | 2021 |
Serum matrix metalloproteinase 7 and accelerated glomerular filtration rate decline in a general non-diabetic population.
Topics: Disease Progression; Glomerular Filtration Rate; Humans; Iohexol; Matrix Metalloproteinase 2; Matrix | 2022 |
Routinely measured iohexol glomerular filtration rate versus creatinine-based estimated glomerular filtration rate as predictors of mortality in patients with advanced chronic kidney disease: a Swedish Chronic Kidney Disease Registry cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Contrast Media; Creatinine; Female; Glom | 2017 |
Validation of a routine two-sample iohexol plasma clearance assessment of GFR and an evaluation of common endogenous markers in a rat model of CKD.
Topics: Animals; Biomarkers; Contrast Media; Glomerular Filtration Rate; Inulin; Iohexol; Male; Metabolic Cl | 2017 |
CKD-EPI equation: A suitable Glomerular Filtration Rate estimate for drug dosing in HIV-infected patients.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2017 |
Estimating glomerular filtration rate (GFR) in children. The average between a cystatin C- and a creatinine-based equation improves estimation of GFR in both children and adults and enables diagnosing Shrunken Pore Syndrome.
Topics: Adolescent; Adult; Biomarkers; Child; Child, Preschool; Contrast Media; Creatinine; Cystatin C; Fema | 2017 |
Performance of glomerular filtration rate estimation equations in Congolese healthy adults: The inopportunity of the ethnic correction.
Topics: Adult; Algorithms; Creatinine; Cross-Sectional Studies; Cystatin C; Democratic Republic of the Congo | 2018 |
Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Contrast Media; Female; Glomerular Filtration Rate; Huma | 2018 |
Iohexol-measured glomerular filtration rate in children and adolescents with chronic kidney disease: a pilot study comparing venous and finger stick methods: response to comments from Dr. Luis-Lima.
Topics: Adolescent; Child; Creatinine; Glomerular Filtration Rate; Humans; Iohexol; Pilot Projects; Renal In | 2019 |
Response to "Iohexol-measured glomerular filtration rate in children and adolescents with chronic kidney disease: a pilot study comparing venous and finger stick methods".
Topics: Adolescent; Child; Creatinine; Glomerular Filtration Rate; Humans; Iohexol; Pilot Projects; Renal In | 2019 |
Glomerular Hyper- and Hypofiltration During Acute Circulatory Failure: Iohexol-Based Gold-Standard Descriptive Study.
Topics: Adult; Creatinine; Critical Illness; Female; Humans; Intensive Care Units; Iohexol; Kidney Function | 2019 |
Blood lead level and measured glomerular filtration rate in children with chronic kidney disease.
Topics: Adolescent; Canada; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Environmental | 2013 |
Applicability of a different estimation equation of glomerular filtration rate in Turkey.
Topics: Adult; Aged; Asian People; Contrast Media; Creatinine; Cross-Sectional Studies; Female; Glomerular F | 2013 |
Estimating kidney function in HIV-infected adults in Kenya: comparison to a direct measure of glomerular filtration rate by iohexol clearance.
Topics: Adolescent; Adult; Female; Glomerular Filtration Rate; HIV Infections; Humans; Iohexol; Kenya; Kidne | 2013 |
The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Body Mass Index; Cohort Studies; Creatinine; Female; Gl | 2014 |
Predicting the glomerular filtration rate in bariatric surgery patients.
Topics: Adult; Bariatric Surgery; Body Surface Area; Body Weight; Creatinine; Cystatin C; Female; Glomerular | 2014 |
An efficient approach for glomerular filtration rate assessment in older adults.
Topics: Aged; Aged, 80 and over; Anthropometry; Area Under Curve; Biomarkers; Chromatography, High Pressure | 2014 |
Accuracy of GFR estimation in obese patients.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Body Surface Area; Body Weight; Contrast Media; Fem | 2014 |
Factors affecting glomerular filtration rate, as measured by iohexol disappearance, in men with or at risk for HIV infection.
Topics: Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Glomerular Filtration Rate; HIV Infections; | 2014 |
Performance of formulas for estimating glomerular filtration rate in Indigenous Australians with and without Type 2 diabetes: the eGFR Study.
Topics: Australia; Creatinine; Diabetes Mellitus, Type 2; Diet, Diabetic; Early Diagnosis; Female; Glomerula | 2014 |
Correlates of leptin in children with chronic kidney disease.
Topics: Adolescent; Body Mass Index; Child; Cholesterol, HDL; Cohort Studies; Contrast Media; Cross-Sectiona | 2014 |
Extended renal outcomes with use of iodixanol versus iohexol after coronary angiography.
Topics: Acute Kidney Injury; Age Distribution; Aged; Cohort Studies; Contrast Media; Coronary Angiography; F | 2014 |
Application of plasma clearance of iohexol in evaluating renal function in chinese children with chronic kidney disease.
Topics: Child; Glomerular Filtration Rate; Humans; Iohexol; Renal Insufficiency, Chronic; Technetium Tc 99m | 2015 |
Contrast-induced nephropathy following chronic total occlusion percutaneous coronary intervention in patients with chronic kidney disease.
Topics: Acute Kidney Injury; Aged; Contrast Media; Coronary Occlusion; Female; Glomerular Filtration Rate; H | 2015 |
Midlife Blood Pressure and Late-Life GFR and Albuminuria: An Elderly General Population Cohort.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Albuminuria; Cohort Studies; Contrast Media; Creatinine | 2015 |
Iohexol plasma clearance measurement in older adults with chronic kidney disease-sampling time matters.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Contrast Media; Creatinine; Cross-Sectio | 2015 |
Iohexol interference in the α2-globulin fraction of the serum protein capillary electrophoresis.
Topics: Aged; Alpha-Globulins; Coronary Angiography; Electrophoresis, Capillary; Humans; Iohexol; Male; Rena | 2015 |
Estimated and Measured GFR Associate Differently with Retinal Vasculopathy in the General Population.
Topics: Contrast Media; Creatinine; Cystatin C; Female; Glomerular Filtration Rate; Humans; Iohexol; Kidney | 2015 |
Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots.
Topics: Child; Child, Preschool; Contrast Media; Dried Blood Spot Testing; Female; Glomerular Filtration Rat | 2015 |
Concordance Between Iothalamate and Iohexol Plasma Clearance.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Chromatography, Liquid; Contrast Media; Creatinin | 2016 |
Elevated blood pressure is not associated with accelerated glomerular filtration rate decline in the general non-diabetic middle-aged population.
Topics: Blood Pressure; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Iohexol | 2016 |
Ultralow Iodine Dose Transarterial Catheter-Directed CT Angiography for Fenestrated Endovascular Aortic Repair Planning.
Topics: Aortic Aneurysm, Abdominal; Aortography; Biomarkers; Catheterization, Peripheral; Computed Tomograph | 2016 |
Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times.
Topics: Adolescent; Body Surface Area; Child; Child, Preschool; Contrast Media; Female; Humans; Infant; Iohe | 2017 |
Long-Term Adverse Effects of Low-Osmolar Compared With Iso-Osmolar Contrast Media After Coronary Angiography.
Topics: Aged; Cause of Death; China; Contrast Media; Coronary Angiography; Female; Heart Failure; Humans; In | 2016 |
Preoperative Evaluation of the Renal Function before the Treatment of Abdominal Aortic Aneurysms.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Biomarkers; Contrast Media; Creatinine; Female; | 2017 |
Identifying subgroups of renal function trajectories.
Topics: Cohort Studies; Creatinine; Glomerular Filtration Rate; Humans; Iohexol; Registries; Renal Insuffici | 2017 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
New equations to estimate GFR in children with CKD.
Topics: Adolescent; Biometry; Blood Urea Nitrogen; Body Height; Child; Child, Preschool; Cohort Studies; Con | 2009 |
Longitudinal formulas to estimate GFR in children with CKD.
Topics: Adolescent; Child; Child, Preschool; Contrast Media; Female; Follow-Up Studies; Glomerular Filtratio | 2009 |
[GFR estimation based upon cystatin C concentration as a substance marker--proposal of a new formula].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cystatin C; Female; Glomerular Filtration Ra | 2009 |
A new tool for predicting the probability of chronic kidney disease from a specific value of estimated GFR.
Topics: Adult; Female; Glomerular Filtration Rate; Humans; Iohexol; Kidney Failure, Chronic; Logistic Models | 2010 |
Impaired fasting glucose is associated with renal hyperfiltration in the general population.
Topics: Blood Glucose; Fasting; Female; Glomerular Filtration Rate; Glucose Intolerance; Glycated Hemoglobin | 2011 |
Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function.
Topics: Aged; Antibodies, Monoclonal; Case-Control Studies; Creatinine; Cystatin C; Glomerular Filtration Ra | 2012 |
Long-term effect of radiocontrast-enhanced computed tomography on the renal function of chronic kidney disease patients.
Topics: Aged; Contrast Media; Female; Glomerular Filtration Rate; Humans; Iohexol; Kidney; Kidney Failure, C | 2012 |
Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C.
Topics: Adolescent; Biomarkers; Blood Urea Nitrogen; Body Height; Canada; Child; Child, Preschool; Cohort St | 2012 |
Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C.
Topics: Adolescent; Biomarkers; Blood Urea Nitrogen; Body Height; Canada; Child; Child, Preschool; Cohort St | 2012 |
Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C.
Topics: Adolescent; Biomarkers; Blood Urea Nitrogen; Body Height; Canada; Child; Child, Preschool; Cohort St | 2012 |
Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C.
Topics: Adolescent; Biomarkers; Blood Urea Nitrogen; Body Height; Canada; Child; Child, Preschool; Cohort St | 2012 |
Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals.
Topics: Anti-HIV Agents; Biomarkers; Creatinine; Cystatin C; Female; Glomerular Filtration Rate; HIV Seropos | 2012 |
Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly.
Topics: Aged; Aged, 80 and over; Cohort Studies; Creatinine; Feeding Behavior; Female; Glomerular Filtration | 2013 |
Two novel equations to estimate kidney function in persons aged 70 years or older.
Topics: Aged; Aged, 80 and over; Biomarkers; Creatinine; Cross-Sectional Studies; Cystatin C; Female; Glomer | 2012 |
Effect of renin-angiotensin-aldosterone system blockade therapy on incidence of contrast-induced nephropathy in patients with chronic kidney disease.
Topics: Acute Kidney Injury; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme In | 2012 |
CT pulmonary angiography in elderly patients: outcomes in patients aged >85 years.
Topics: Age Factors; Aged, 80 and over; Contrast Media; Female; Humans; Iohexol; Male; Patient Safety; Pulmo | 2013 |
Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Contrast Media; Female; Fluid Therapy; Humans; Iohexol; K | 2005 |